Imaging for Cardiotoxicity: Many Issues, Many Questions Mini-review: key problems in cardio-oncology
Article Sidebar
Published:
Mar 18, 2016
Main Article Content
Abstract
None
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Szmit S. Imaging for Cardiotoxicity: Many Issues, Many Questions. OncoReview [Internet]. 2016Mar.18 [cited 2024Nov.23];6(1(21):18-3. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/472
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Romond EH, Jeong JH, Rastogi P et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30(31): 3792-3799.
2. Wang L, Tan TC, Halpern EF et al. Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. Am J Cardiol 2015; 116(3): 442-446.
3. Dorosz JL, Lezotte DC, Weitzenkamp DA et al. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol 2012; 59(20): 1799-1808.
4. Walker J, Bhullar N, Fallah-Rad N et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010; 28(21): 3429-3436.
5. Thavendiranathan P, Grant AD, Negishi T et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013; 61(1): 77-84.
6. Cardinale D, Colombo A, Bacchiani G et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131(22): 1981-1988.
7. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55(3): 213-220.
8. Ewer MS, Ali MK, Mackay B et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 1984; 2(2): 112-117.
9. Mousavi N, Tan TC, Ali M et al. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging 2015; 16(9): 977-984.
10. Sawaya H, Sebag IA, Plana JC et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011; 107(9): 1375-1380.
11. Negishi K, Negishi T, Hare JL et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013; 26(5): 493-498.
12. Thavendiranathan P, Poulin F, Lim KD et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014; 63(25 Pt A): 2751-2768.
13. Ho E, Brown A, Barrett P et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010; 96(9): 701-707.
14. Cheung YF, Hong WJ, Chan GC et al. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy. Heart 2010; 96(14): 1137-1141.
15. Negishi K, Negishi T, Haluska BA et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 2014; 15(3): 324-331.
16. Ambale-Venkatesh B, Lima JA. Cardiac MRI: a central prognostic tool in myocardial fibrosis. Nat Rev Cardiol 2015; 12(1): 18-29.
17. Neilan TG, Coelho-Filho OR, Shah RV et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol 2013; 111(5): 717-722.
18. Toro-Salazar OH, Gillan E, O’Loughlin MT, Burke GS et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging 2013; 6(6): 873-880.
19. Armstrong GT, Plana JC, Zhang N et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012; 30(23): 2876-2884.
20. Neilan TG, Coelho-Filho OR, Pena-Herrera D et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol 2012; 110(11): 1679-1686.
21. Drafts BC, Twomley KM, D’Agostino R Jr. et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013; 6(8): 877-885.
22. Francis SA, Cheng S, Arteaga CL, Moslehi J. Heart failure and breast cancer therapies: moving towards personalized risk assessment. J Am Heart Assoc 2014; 3(1): e000780.
23. Hole T, Otterstad JE, St John Sutton M et al. Differences between echocardiographic measurements of left ventricular dimensions and function by local investigators and a core laboratory in a 2-year follow-up study of patients with an acute myocardial infarction. Eur J Echocardiogr 2002; 3(4): 263-270.
24. Chung ES, Leon AR, Tavazzi L et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008; 117(20): 2608-2616.
25. Foster E, Wasserman HS, Gray W et al. Quantitative assessment of severity of mitral regurgitation by serial echocardiography in a multicenter clinical trial of percutaneous mitral valve repair. Am J Cardiol 2007; 100(10): 1577-1583.
26. Douglas PS, DeCara JM, Devereux RB et al. American Society of Echocardiography Standards; American College of Cardiology Foundation. Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation. J Am Soc Echocardiogr 2009; 22(7): 755-765.
27. Acker MA, Bolling S, Shemin R, Kirklin J et al. Acorn Trial Principal Investigators and Study Coordinators. Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. J Thorac Cardiovasc Surg 2006; 132(3): 568-577, 577.e1-4.
28. Douglas PS, Waugh RA, Bloomfield G et al. Implementation of echocardiography core laboratory best practices: a case study of the PARTNER I trial. J Am Soc Echocardiogr 2013; 26(4): 348-358.e3.
29. Oh JK, Pellikka PA, Panza JA et al. STICH Trial Investigators. Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. J Am Soc Echocardiogr. 2012; 25(3): 327-336.
30. Panza JA, Velazquez EJ, She L et al. Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]. J Am Coll Cardiol 2014; 64(6): 553-561.
31. Gierada DS, Garg K, Nath H et al. CT quality assurance in the lung screening study component of the National Lung Screening Trial: implications for multicenter imaging trials. AJR Am J Roentgenol 2009; 193(2): 419-424.
32. Daubert MA, Yow E, Barnhart HX et al. Quality Improvement Implementation: Improving Reproducibility in the Echocardiography Laboratory. J Am Soc Echocardiogr 2015; 28(8): 959-968.
33. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 2014; 3(1): e000472.
34. Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014; 15(10): 1063-1093.
35. Advani PP, Ballman KV, Dockter TJ et al. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol 2016; 34(6): 581-587.
36. Morris PG, Dickler M, McArthur HL et al. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent shortterm changes in left ventricular ejection fraction. J Clin Oncol 2009; 27(36): 6117-6123.
37. Chavez-MacGregor M, Niu J, Zhang N et al. Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. J Clin Oncol 2015; 33(19): 2176-2183.
2. Wang L, Tan TC, Halpern EF et al. Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. Am J Cardiol 2015; 116(3): 442-446.
3. Dorosz JL, Lezotte DC, Weitzenkamp DA et al. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol 2012; 59(20): 1799-1808.
4. Walker J, Bhullar N, Fallah-Rad N et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010; 28(21): 3429-3436.
5. Thavendiranathan P, Grant AD, Negishi T et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013; 61(1): 77-84.
6. Cardinale D, Colombo A, Bacchiani G et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131(22): 1981-1988.
7. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55(3): 213-220.
8. Ewer MS, Ali MK, Mackay B et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 1984; 2(2): 112-117.
9. Mousavi N, Tan TC, Ali M et al. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging 2015; 16(9): 977-984.
10. Sawaya H, Sebag IA, Plana JC et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011; 107(9): 1375-1380.
11. Negishi K, Negishi T, Hare JL et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013; 26(5): 493-498.
12. Thavendiranathan P, Poulin F, Lim KD et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014; 63(25 Pt A): 2751-2768.
13. Ho E, Brown A, Barrett P et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010; 96(9): 701-707.
14. Cheung YF, Hong WJ, Chan GC et al. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy. Heart 2010; 96(14): 1137-1141.
15. Negishi K, Negishi T, Haluska BA et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 2014; 15(3): 324-331.
16. Ambale-Venkatesh B, Lima JA. Cardiac MRI: a central prognostic tool in myocardial fibrosis. Nat Rev Cardiol 2015; 12(1): 18-29.
17. Neilan TG, Coelho-Filho OR, Shah RV et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol 2013; 111(5): 717-722.
18. Toro-Salazar OH, Gillan E, O’Loughlin MT, Burke GS et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging 2013; 6(6): 873-880.
19. Armstrong GT, Plana JC, Zhang N et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012; 30(23): 2876-2884.
20. Neilan TG, Coelho-Filho OR, Pena-Herrera D et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol 2012; 110(11): 1679-1686.
21. Drafts BC, Twomley KM, D’Agostino R Jr. et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013; 6(8): 877-885.
22. Francis SA, Cheng S, Arteaga CL, Moslehi J. Heart failure and breast cancer therapies: moving towards personalized risk assessment. J Am Heart Assoc 2014; 3(1): e000780.
23. Hole T, Otterstad JE, St John Sutton M et al. Differences between echocardiographic measurements of left ventricular dimensions and function by local investigators and a core laboratory in a 2-year follow-up study of patients with an acute myocardial infarction. Eur J Echocardiogr 2002; 3(4): 263-270.
24. Chung ES, Leon AR, Tavazzi L et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008; 117(20): 2608-2616.
25. Foster E, Wasserman HS, Gray W et al. Quantitative assessment of severity of mitral regurgitation by serial echocardiography in a multicenter clinical trial of percutaneous mitral valve repair. Am J Cardiol 2007; 100(10): 1577-1583.
26. Douglas PS, DeCara JM, Devereux RB et al. American Society of Echocardiography Standards; American College of Cardiology Foundation. Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation. J Am Soc Echocardiogr 2009; 22(7): 755-765.
27. Acker MA, Bolling S, Shemin R, Kirklin J et al. Acorn Trial Principal Investigators and Study Coordinators. Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. J Thorac Cardiovasc Surg 2006; 132(3): 568-577, 577.e1-4.
28. Douglas PS, Waugh RA, Bloomfield G et al. Implementation of echocardiography core laboratory best practices: a case study of the PARTNER I trial. J Am Soc Echocardiogr 2013; 26(4): 348-358.e3.
29. Oh JK, Pellikka PA, Panza JA et al. STICH Trial Investigators. Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. J Am Soc Echocardiogr. 2012; 25(3): 327-336.
30. Panza JA, Velazquez EJ, She L et al. Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]. J Am Coll Cardiol 2014; 64(6): 553-561.
31. Gierada DS, Garg K, Nath H et al. CT quality assurance in the lung screening study component of the National Lung Screening Trial: implications for multicenter imaging trials. AJR Am J Roentgenol 2009; 193(2): 419-424.
32. Daubert MA, Yow E, Barnhart HX et al. Quality Improvement Implementation: Improving Reproducibility in the Echocardiography Laboratory. J Am Soc Echocardiogr 2015; 28(8): 959-968.
33. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 2014; 3(1): e000472.
34. Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014; 15(10): 1063-1093.
35. Advani PP, Ballman KV, Dockter TJ et al. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol 2016; 34(6): 581-587.
36. Morris PG, Dickler M, McArthur HL et al. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent shortterm changes in left ventricular ejection fraction. J Clin Oncol 2009; 27(36): 6117-6123.
37. Chavez-MacGregor M, Niu J, Zhang N et al. Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. J Clin Oncol 2015; 33(19): 2176-2183.